Medical bottles and syringe are seen with Novo Nordisk logo displayed on a screen in the background.
Nurphoto | Nurphoto | Getty Images
Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop 15.7% of their weight after 68 weeks.
The company’s stock was down 5.4% at 11:22 a.m. London time.
Novo Nordisk, which manufactures the fiercely popular weight-loss drug Wegovy, previously forecast weight loss of 25% for patients who take CagriSema. In another late-trial result published in December, the company found CagriSema helped patients reduce their weight by 22.7% in that test.
CagriSema is being investigated by Novo Nordisk as a weight-loss drug for adults who are overweight or obese, as well as a treatment for adults with type 2 diabetes. The company currently expects to file for regulatory approval for CagriSema in the first quarter of 2026.
This breaking news story is being updated.
Discover more from Latest News Today
Subscribe to get the latest posts sent to your email.
